Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:44:17 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Q:STRO - SUTRO BIOPHARMA INC - http://www.sutrobio.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
STRO - Q0.33.39·3.912.53.63-0.14-3.7515.91,6902,9823.73  3.80  3.556.13  2.00516:35:29Apr 0215 min RT 2¢

Recent Trades - Last 10 of 2982
Time ETExPriceChangeVolume
16:35:29Q3.72-0.051
16:31:54Q3.50-0.271
16:30:43Q3.63-0.141
16:30:12Q3.63-0.1464
16:20:00Q3.63-0.14134
16:12:59Q3.910.1410
16:09:12Q3.910.141
16:09:11Q3.50-0.271
16:08:37Q3.53-0.241
16:08:37Q3.51-0.261

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-02 06:19U:STRONews ReleaseSutro Biopharma Announces Pricing of $75 Million Underwritten Offering
2024-03-25 16:30U:STRONews ReleaseSutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2024-02-06 16:05U:STRONews ReleaseSutro Biopharma to Participate in Upcoming Investor Conferences
2024-01-04 16:05U:STRONews ReleaseSutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolR Ž ±-targeting ADC
2023-12-14 16:05U:STRONews ReleaseSutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR Ž ±-targeted ADC, on January 4, 2024
2023-12-11 16:05U:STRONews ReleaseSutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
2023-12-04 16:05U:STRONews ReleaseSutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
2023-11-27 16:00U:STRONews ReleaseVaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
2023-11-21 16:05U:STRONews ReleaseSutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
2023-11-13 16:30U:STRONews ReleaseSutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2023-10-22 04:25U:STRONews ReleaseSutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
2023-10-16 16:05U:STRONews ReleaseSutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference
2023-09-19 08:00U:STRONews ReleaseSutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer
2023-08-30 08:00U:STRONews ReleaseSutro Biopharma to Participate in Upcoming Investor Conferences
2023-08-10 16:30U:STRONews ReleaseSutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2023-06-26 08:00U:STRONews ReleaseSutro Biopharma and Blackstone Announce Royalty Financing Collaboration
2023-06-03 16:00U:STRONews ReleaseSutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1
2023-05-31 08:00U:STRONews ReleaseSutro Biopharma to Participate in the Jefferies Healthcare Conference
2023-05-15 08:00U:STRONews ReleaseSutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2023-05-08 08:00U:STRONews ReleaseSutro Biopharma to Present at the JMP Securities Life Sciences Conference